Gordon R. Greenberg

Mount Sinai Hospital
Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Preoperative Anti-tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After Ileal Pouch-anal Anastomosis.

Preoperative Anti-tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After Ileal Pouch-anal Anastomosis.

Journal: Inflammatory bowel diseases

Published: September 09, 2016

Rates and Predictors of Endoscopic and Clinical Recurrence After Primary Ileocolic Resection for Crohn's Disease.

Rates and Predictors of Endoscopic and Clinical Recurrence After Primary Ileocolic Resection for Crohn's Disease.

Journal: Digestive diseases and sciences

Published: October 12, 2015

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.

Journal: Lancet (London, England)

Published: September 07, 2015

Predictors of Outcome in Ulcerative Colitis.

Predictors of Outcome in Ulcerative Colitis.

Journal: Inflammatory bowel diseases

Published: July 16, 2015

Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.

Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.

Journal: Inflammatory bowel diseases

Published: June 23, 2015

Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis.

Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis.

Journal: Journal of Crohn's & colitis

Published: June 21, 2015

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.

Journal: Gut

Published: June 20, 2014

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.

Journal: Alimentary pharmacology & therapeutics

Published: October 23, 2013

Ileal pouch symptoms do not correlate with inflammation of the pouch.

Ileal pouch symptoms do not correlate with inflammation of the pouch.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: June 21, 2013

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

Journal: Gastroenterology

Published: April 16, 2013

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

Journal: Alimentary pharmacology & therapeutics

Published: April 10, 2013

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Journal: The New England journal of medicine

Published: October 19, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026